Loading...
•
Dec 31, 2025
LivaNova Q4 2025 Earnings Report
LivaNova reported double-digit revenue growth and higher operating income in Q4 2025, with improved EPS year over year.
Key Takeaways
LivaNova delivered 12.1% revenue growth in Q4 2025, driven by strength in Cardiopulmonary and Neuromodulation. Operating income increased year over year, and adjusted EPS improved to $0.86, reflecting margin expansion despite lower GAAP net income compared to the prior year.
Total revenue increased 12.1% year over year to $360900000.
Operating income rose to $42600000 from $37000000 in the prior year period.
Adjusted operating income increased to $63800000, expanding adjusted operating margin to 17.7%.
Adjusted diluted EPS improved to $0.86 from $0.81 year over year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
For full-year 2026, LivaNova expects constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted EPS in the range of $4.15 to $4.25, with adjusted free cash flow between $160000000 and $180000000.
Positive Outlook
- Expected constant-currency revenue growth between 6.0% and 7.0%.
- Adjusted diluted EPS guidance of $4.15 to $4.25.
- Foreign currency expected to provide approximately 1.0% tailwind.
- Adjusted free cash flow projected between $160000000 and $180000000.
- Increased Medicare reimbursement for VNS Therapy effective January 1, 2026.
Challenges Ahead
- Guidance excludes unpredictable GAAP adjustments.
- Exposure to foreign currency fluctuations.
- Ongoing legal and environmental liabilities, including SNIA.
- Potential impact from financing-related costs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...